Cynata Therapeutics Ltd has released a press release.
Cynata Receives $1.892m R&D Tax Incentive Refund
Filed with ASX ·
6ix hasn’t read this filing yet.
Cynata Therapeutics Limited on 6ix
Story so far
Earlier from Cynata Therapeutics
- Cymerus MSCs Effective in Preclinical Model of Sepsis
- CYP Files Application to Commence Phase 2 CLI Clinical Trial
- Cynata Awarded Grant for Coronary Artery Disease Study
- Notice of Allowance from CIPO for Patent Application
- September 2019 Quarterly Report
Later from Cynata Therapeutics
- Cynata Receives UK Regulatory Approval for CLI Trial
- Cynata Therapeutics: UK Regulatory Authority Approves Cynata’s Phase 2 Clinical Trial in Critical Limb Ischaemia
- December 2019 Quarterly Report
- Notice of Allowance from Israel Patent Office
- Market Update & Additional A$618k R&D Tax Refund
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics